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Metastasis is of dismal prognosis for cancer patients, but recent evidence in mouse
models of cancer shows that metastasis prevention is a reachable clinical objective.
These experiments indicate that altered mitochondrial activities are associated with
the metastatic phenotype. Mitochondrial transfer from metastatic to non-metastatic
cells can indeed transfer the metastatic phenotype, and metastatic progenitor cells
differ from other cancer cells by a higher sublethal production of mitochondrial
reactive oxygen species (ROS). Moreover, mitochondria-targeted antioxidants can
prevent metastatic dissemination in mouse models of cancer. Comparatively, general
antioxidants have unpredictable effects on cancer metastasis, most probably because
they affect several cell types, several subcellular ROS production sites and, often,
several endogenous oxidant species. Thus, targeting antioxidants to mitochondria could
improve their antimetastatic activities, as previously exemplified with mitochondria-
targeted mitoTEMPO and mitoQ that can prevent metastatic dissemination in cancer-
bearing mice. Our objective in this study was to identify whether catechins, which
are known to be potent antioxidants, can inhibit cancer cell migration in vitro and
metastatic take in vivo. Comparative analysis of the response to epigallocatechin-
3-gallate, (+)-catechin and (+)-catechin:lysine complexes revealed that, whereas all
compounds had similar general antioxidant properties, (+)-catechin:lysine 1:2, but
not epigallocatechin-3-gallate, can prevent metastatic take of melanoma cells to the
lungs of mice. (+)-Catechin:lysine 1:2 possesses two net positive charges provided by
lysines at physiological pH, which could provide high affinity for the negatively charged
mitochondrial matrix. While this study reveals that (+)-catechin:lysine 1:2 has interesting
antimetastatic effects, future experiments are needed to formally demonstrate the
stability of the complex, its effective tropism for mitochondria and whether or not its
activity can be globally attributed to its antioxidant activity at this precise subcellular
location.
Keywords: polyphenols, epigallocatechin gallate (EGCG), (+)-catechin, cyanidanol-3, reactive oxygen species
(ROS), cancer cell migration, cancer metastasis, cancer therapy
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INTRODUCTION
Cancer is a progressive disease. At advanced stages, most solid
tumors undergo a metastatic switch, marking the transition from
local to systemic disease, which seriously limits cancer curability.
Often, local interventions, such as surgery and radiotherapy, can
indeed not be applied to highly metastatic tumors. Metastases
are responsible for the death of ∼90% of all cancer patients
(Gupta and Massague, 2006), which constitutes a strong incentive
to develop and validate new treatments capable of selectively
preventing or eradicating metastases.
It is estimated that tumors in the metastatic phase shed
approximately one million of cancer cells per gram of tumor
in the circulation every day (Liotta et al., 1974; Butler and
Gullino, 1975; Chang et al., 2000). Of these cells, only few,
termed metastatic progenitor cells, simultaneously possess all
the characteristics needed to successfully establish a secondary
tumor, including resistance to anoikis, directional migration,
invasiveness, and clonogenicity. These metastatic progenitor cells
represent only ∼0.01% of all circulating cancer cells (Langley
and Fidler, 2011), but constitute a major target for metastatic
prevention. Even if they are scarce, their characterization is
possible.
Experimental work in vitro and in mouse models previously
demonstrated that mitochondria within cancer cells control
metastasis by modulating reactive oxygen species (ROS)
production. The seminal work of Ishikawa et al. (2008) indeed
showed that the transfer of ROS-producing mitochondria from
metastatic to non-metastatic cancer cells also transfers the
metastatic phenotype. More recently, based on the natural
selection of superinvasive and supermetastatic cancer cells from
weakly invasive and weakly metastatic precursors and their
metabolic comparison, we identified mitochondrial superoxide
produced at the electron transport chain (ETC) as a major
metastatic trigger (Porporato et al., 2014). When produced in
mitochondria, superoxide activates Src kinase directly within
mitochondria, thereby activating transforming growth factor β
(TGF-β) signaling independently of TGF-β. Increased superoxide
production by mitochondria, whether naturally selected or
experimentally induced by ETC bottlenecking (with, e.g., low
dose rotenone), was sufficient to induce cancer cell migration,
invasion and metastasis in mice. Tan et al. (2015) further
showed that cancer cells lacking mitochondria can engulf,
coopt and activate mitochondria provided by stromal cells
during the metastatic cascade, thus restoring this source of
ROS. Consequently, selective inactivation of mitochondrial
superoxide production with mitochondria-targeted antioxidants
was shown to highly significantly prevent spontaneous metastatic
dissemination in mice (Porporato et al., 2014), paving the way for
future clinical interventions (Porporato and Sonveaux, 2015).
General antioxidants have been the subject of intense research
for cancer prevention and treatment. Because these molecules
indistinctively target different cell types (including tumor-
resident non-malignant host cells, some of which promote and
some of which repress tumor progression), because they are
not selective for a given ROS produced at a precise subcellular
location and because they can interfere with anticancer therapy,
general antioxidants have unpredictable effects on cancer
progression (Bonner and Arbiser, 2014; Milkovic et al., 2014;
Ozben, 2015; Assi and Rebillard, 2016; Russo et al., 2017). For
examples, chronic vitamin E supplementation was found to
significantly increase prostate cancer incidence in humans (Klein
et al., 2011), vitamin C has no significant anticancer effects
even when administered intravenously at high dose (Jacobs
et al., 2015), and N-acetylcysteine can promote metastasis by
improving the resistance of cancer cells to oxidative stress
during cell detachment and in the blood stream (Le Gal
et al., 2015). Comparatively, stronger evidence indicates that
metastatic dissemination can be prevented by selectively targeting
superoxide production by the dysfunctional mitochondria of
metastatic progenitor cells in mice (Porporato et al., 2015), but
efficient compounds must still be identified for future clinical
applications.
In the present study, we aimed to determine whether catechins
could be used for metastatic prevention. These polyphenols are
potent antioxidants, but, even if they can modulate mitochondrial
functions (Oliveira et al., 2016), they lack selectivity and can
affect many signaling pathways (Singh et al., 2011). We focused
on (+)-catechin (also known as cyanidanol-3), which can be
extracted with high yield and purity using traditional solvent-
based methods from Uncaria gambir, a plant found in Southeast
Asia (Niebes et al., 1981). In theory, this compound is more stable
than epigallocatechin-3-gallate (EGCG, the main catechin found
in green tea and currently tested in 37 clinical trials for cancer
patients1), which undergoes auto-oxidation and epimerization
in water (Das and Griffiths, 1967; Sang et al., 2005). Of further
interest, (+)-catechin has been reported to form complexes with
one or two lysines, which further increases its water solubility
and brings a net positive charge (−NH3+) to the catechin at
physiological pH (Niebes et al., 1981). The net positive charge of
these complexes is of interest, because it could target (+)-catechin
to the negatively charged mitochondrial matrix, in a way similar
to antioxidants 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO)
and coenzyme Q10 that can be targeted to mitochondria when
a positively charged triphenylphosphonium (TPP) group is
chemically grafted on these molecules to yield mitoTEMPO and
mitoQ, respectively (Murphy, 2008). Using EGCG as a reference
compound, we therefore studied the potential antimetastatic
effects of (+)-catechin and (+)-catechin:lysine complexes in vitro
and in vivo.
MATERIALS AND METHODS
Cells and Cell Culture
Wild-type B16F10 mouse melanoma and SiHa human cervix
adenocarcinoma cells were from ATCC. Superinvasive SiHa-F3
cells were obtained by serial in vitro selection, as previously
described (Porporato et al., 2014). Cell lines were routinely
cultured at subconfluence for no more than 15 passages in
DMEM containing 4.5 g/L glucose and GlutaMAX (Gibco),
supplemented with 10% FBS (Sigma–Aldrich) and 1%
1clinicaltrials.gov
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penicillin/streptomycin (Sigma–Aldrich) in a humidified
atmosphere with 5% CO2 at 37◦C.
Chemicals
(+)-Catechin [(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-
1(2H)-benzopyran-3,5,7-triol], also known as cyanidanol-3,
was extracted and purified from U. gambir according to Niebes
et al. (1981), reaching ≥99% purity. EGCG and D/L-lysine
monohydrochloride were from Sigma–Aldrich. For the
production of catechin/lysine complexes, catechin powder
was mixed with DL-lysine monohydrochloride at a 1:1 or 1:2
(mol/mol) ratio before dissolution in culture medium buffered at
pH 7.4. Where indicated, rotenone was used at low nanomolar
concentration in order to promote mitochondrial superoxide
production, cell migration and experimental metastasis,
according to Porporato et al. (2014). Unless specified otherwise,
all other chemicals were from Sigma–Aldrich.
Cell Viability Assay
Twenty thousand SiHa-F3 or B16F10 cells per well were seeded
in a 96-well plate containing culture medium together with test
compounds, and incubated for 16 h. Cells were washed with
PBS, fixed in methanol for 3 min, stained with a 0.23% water
solution of Crystal Violet for 30 min, and washed with water.
Crystal Violet precipitates were resuspended in 200 µl of DMSO,
and absorbance was measured at 595 nm with a Victor X4
spectrophotometer (Perkin-Elmer).
MTT Assay
Twenty thousand SiHa-F3 cells per well were seeded in a 96-well
plate containing culture medium together with test compounds,
and incubated for 16 h. Cells were washed with HBSS buffer
(containing Ca2+/Mg2+ and 10 mM of HEPES), and incubated
for 3 h with a saturated solution of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, Calbiochem) in HBSS.
Formazan precipitates were resuspended in 50 µl of DMSO,
and absorbance was measured at 570 nm with a Victor X4
spectrophotometer.
ROS Measurements
Twenty thousand SiHa-F3 or B16F10 cells per well were seeded in
a 96-well plate containing culture medium. On the next day, they
were treated with rotenone and/or test compounds or vehicle
for 1 h (SiHa-F3) or 6 h (B16F10), washed with HBSS, and
ROS were measured using 1 µM of CM-H2-dichlorofluorescein-
diacetate (CM-H2-DCFDA, Life technologies) as previously
reported (Porporato et al., 2014). Fluorescence emission at
535 nm following excitation at 490 nm was measured with
a Victor X4 spectrophotometer, and data were normalized to
protein content (Bradford).
Cell Migration
A 48-well micro-chemotaxis chamber (8-µm diameter pores;
Neuroprobe) and transwell inserts (Corning #353097) were used
as previously described (Porporato et al., 2014), with 0.15%
(SiHa-F3) or 0.5% (B16F10) FBS as a chemo-attractant. Fifty
thousand SiHa-F3 cells or two hundred thousand B16F10 cells
per well were allowed to migrate during 16 h. Migrated cells were
then fixed with methanol, stained with Crystal Violet, and imaged
with an inverted phase Axiovert microscope equipped with a Mrc
camera (Zeiss). Cells were counted using the ImageJ software
(NIH). Data were normalized to cell viability.
In Vivo Metastasis Assays
All in vivo experiments were conducted under approval of the
Université catholique de Louvain (UCL) authorities (Comité
d’Ethique Facultaire pour l’Expérimentation Animale) according
to national animal care regulations. Specific authorizations
were UCL/2012/MD/005 and UCL/2016/MD/018. Experimental
metastasis was conducted to assess metastatic take as in
Porporato et al. (2014). Briefly, B16F10 melanoma cells were
treated for 6 h with test compound, rotenone (20 nM dissolved in
0.2% DMSO to induce mitochondrial superoxide production) or
vehicle (DMSO). One million cells were then injected in the tail
vein of 8-weeks-old syngeneic C57BL/6JRj male mice (Janvier).
Mice were sacrificed 2 weeks later. Their lungs were insufflated
with a saline solution, and melanin-containing lung metastases
were counted under a Stemi 2000-C dissection microscope
(Zeiss) equipped with a Mrc camera.
Statistics
Data show means± SEM. N refers to the number of independent
experiments and n to the total number of replicates per treatment
condition. Student’s t-test, one-way ANOVA with Dunnett or
Bonferroni post hoc tests and two-way ANOVA on unmatched
values with Dunnett post hoc test were used as indicated. P < 0.05
was considered to be statistically significant. In some graphs, SEM
are smaller than symbols.
RESULTS
Epigallocatechin-3-gallate Is
Significantly More Antioxidant in SiHa-F3
Cancer Cells than (+)-Catechin,
(+)-Catechin:Lysine 1:1 and
(+)-Catechin:Lysine 1:2
This study aimed to investigate the antimetastatic potential
of catechins. EGCG served as a reference compound, and
its antimetastatic potential was compared to that of (+)-
catechin complexed or not with one or two molecules of lysine
(Figure 1). Compared to EGCG and (+)-catechin that are general
antioxidants, lysine in complexes with catechins could provide a
positive charge for mitochondrial targeting. For in vitro assays,
our model cell line was SiHa-F3, a superinvasive derivative of
human SiHa cervix adenocarcinoma cells that was produced by
in vitro selection and thoroughly characterized in a previous
study (Porporato et al., 2014). Compared to wild-type SiHa, SiHa-
F3 cells produce more mitochondrial superoxide, which directly
accounts for their increased migratory activity, as previously
demonstrated with selective mitochondrial superoxide inhibitor
mitoTEMPO (Porporato et al., 2014).
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FIGURE 1 | Chemical structures. Shown are the chemical structures of the catechins used in this study, as well as models of their interactions with lysines to form
complexes.
We first compared the different compounds for their
antioxidant activities in SiHa-F3 cells. Cells were exposed to
increasing doses of catechins (100 nM to 100 µM) during 1 h,
after which total ROS levels were measured using fluorescent
reporter CM-H2-DCFDA. Side-by-side comparison revealed that
EGCG was significantly more antioxidant than (+)-catechin,
(+)-catechin:lysine 1:1 and (+)-catechin:lysine 1:2 at all the doses
that we tested, except at 100 µM where catechin:lysine 1:1 had
a similar antioxidant activity compared to EGCG (Figure 2A).
Comparison to vehicle treatment was used to identify the
lowest dose at which each compound exerted a significant
antioxidant effect. This dose corresponded to 1 µM for EGCG
(Figure 2B), 10 µM for (+)-catechin (Figure 2C), 100 nM
for (+)-catechin:lysine 1:1 (Figure 2D), and 10 µM for (+)-
catechin:lysine 1:2 (Figure 2E). Of note, D/L-lysine alone did
not affect the total ROS levels of SiHa-F3 cells at concentrations
ranging from 100 nM to 200 µM (Figure 2F).
Epigallocatechin-3-gallate Is
Significantly More Cytotoxic for SiHa-F3
Cancer Cells than (+)-Catechin,
(+)-Catechin:Lysine 1:1 and
(+)-Catechin:Lysine 1:2
We next tested the cytotoxic activity of the different catechins.
SiHa-F3 cells were exposed to increasing doses of catechins
for 16 h, after which their survival was determined using
crystal violet staining. Side-by-side comparison showed that
EGCG was significantly more toxic to SiHa-F3 cells than the
other catechins at doses ≥10 µM (Figure 3A). The lowest
dose inducing cytotoxicity was 10 µM for EGCG (Figure 3B).
(+)-Catechin did not kill SiHa-F3 cancer cells up to 100 µM
(Figure 3C), (+)-catechin:lysine 1:1 induced significant yet
limited cytotoxicity at a dose of 100 µM (Figure 3D), and
(+)-catechin:lysine 1:2 was not toxic at all the tested doses
(Figure 3E). D/L-lysine alone did not affect SiHa-F3 cell viability
(Figure 3F).
Comparison was extended to cell metabolism, and we used a
MTT assay reporting on the activity of intracellular NAD(P)H-
dependent oxidoreductases (Berridge and Tan, 1993). In this
assay, MTT reduction reflects the status of the NAD(P)H pool
inside cells. Side-by-side comparison showed that EGCG reduced
MTT oxidation more significantly than the other compounds
at a dose ≥10 µM (Figure 4A). The lowest effective dose was
10 µM for EGCG (Figure 4B). (+)-catechin did not modify MTT
reduction (Figure 4C), (+)-catechin:lysine 1:1 had a slight but
significant effect at 100 µM (Figure 4D), and (+)-catechin:lysine
1:2 did not modify MTT reduction (Figure 4E). These data
closely matched those obtained in the cytotoxic assay with crystal
violet.
(+)-Catechin:Lysine 1:1 and
(+)-Catechin:Lysine 1:2 Inhibit Cancer
Cell Migration Independently of Cancer
Cell Killing
Cell migration is a fundamental characteristic of metastatic
progenitor cells (Gupta and Massague, 2006), and SiHa-F3 cells
were previously shown to be highly migratory compared to wild-
type SiHa (Porporato et al., 2014). Their increased migratory
activity has been demonstrated to be directly dependent on
an elevated production of mitochondrial superoxide (Porporato
et al., 2014). Because the matrix of functional mitochondria is
negatively charged due to the proton-motive force and since,
unlike EGCG, catechin:lysine complexes have a net positive
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FIGURE 2 | (+)-Catechin derivatives and epigallocatechin-3-gallate (EGCG) have similar general antioxidant effects in SiHa-F3 cancer cells. (A–E) Reactive oxygen
species (ROS) level in SiHa-F3 cells was measured after a 1 h treatment with increasing doses of EGCG (N = 2, n = 8–16), (+)-catechin (N = 2, n = 16), (+)-catechin
in a 1:1 complex with lysine (N = 3, n = 24–32), and (+)-catechin in a 1:2 complex with lysine (N = 2, n = 16–24). The five panels show the same sets of data with
different statistical analyses to compare individual treatments to reference compound EGCG (A) or to vehicle treatment set as 100% (B–E). (A) The graph shows the
dose-response curves of the four treatments for comparison. (B) Dose-response curve for EGCG. (C) Dose-response curve for (+)-catechin. (D) Dose-response
curve for (+)-catechin:lysine 1:1. (E) Dose-response curve for (+)-catechin:lysine 1:2. (F) ROS level in SiHa-F3 cells treated for 1 h with increasing doses of D/L-lysine
monohydrochloride (N = 2, n = 16). All data are shown as means ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005 compared to a same dose of EGCG using two-way
ANOVA; ##P < 0.01, ###P < 0.005 compared to vehicle treatment using one-way ANOVA with Dunnett’s multiple comparison test.
FIGURE 3 | (+)-Catechin and its complexes with lysine are less cytotoxic for SiHa-F3 cancer cells than EGCG. (A–E) SiHa-F3 cell viability was measured by crystal
violet staining following a 16 h treatment with increasing doses of EGCG (N = 2, n = 24), (+)-catechin (N = 2, n = 16–24), (+)-catechin in a 1:1 complex with lysine
(N = 2, n = 15–16), and (+)-catechin in a 1:2 complex with lysine (N = 2, n = 16–24). The five panels show the same sets of data with different statistical analyses to
compare individual treatments to reference compound EGCG (A) or to vehicle treatment set as 100% (B–E). (A) The graph shows the dose-response curves of the
four treatments for comparison. (B) Dose-response curve for EGCG. (C) Dose-response curve for (+)-catechin. (D) Dose-response curve for (+)-catechin:lysine 1:1.
(E) Dose-response curve for (+)-catechin:lysine 1:2. (F) SiHa-F3 cell viability was measured by crystal violet staining following a 16 h treatment with increasing doses
of D/L-lysine monohydrochloride (N = 2, n = 15–16). All data are shown as means ± SEM. ∗∗∗P < 0.005 compared to a same dose of EGCG using two-way
ANOVA; ###P < 0.005 compared to vehicle treatment using one-way ANOVA with Dunnett’s multiple comparison test.
charge (−NH3+ in lysine), we hypothesized that catechin:lysine
complexes could inhibit SiHa-F3 cell migration more efficiently
than EGCG and (+)-catechin.
The anti-migratory potential of increasing doses of catechins
was tested in a micro-chemotaxis chamber with 0.15% of
FBS as chemo-attractant, and the cells were allowed to
migrate during 16 h. Results were normalized to cell death
induced by the different treatments (Figure 3A). Side-by-
side comparison showed that surviving SiHa-F3 cells treated
with (+)-catechin:lysine 1:1 and (+)-catechin:lysine 1:2 were
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FIGURE 4 | (+)-Catechin and its complexes with lysine are less metabolically toxic for SiHa-F3 cancer cells than EGCG. (A–E), The activity of NAD(P)H-dependent
oxidoreductases in SiHa-F3 cells was measured with a MTT assay following a 16-h treatment with increasing doses of EGCG (N = 2, n = 12), (+)-catechin (N = 2,
n = 12), (+)-catechin in a 1:1 complex with lysine (N = 2, n = 16), and (+)-catechin in a 1:2 complex with lysine (N = 2, n = 12). The five panels show the same sets of
data with different statistical analyses to compare individual treatments to reference compound EGCG (A) or to vehicle treatment set as 100% (B–E). (A) The graph
shows the dose-response curves of the four treatments for comparison. (B) Dose-response curve for EGCG. (C) Dose-response curve for (+)-catechin.
(D) Dose-response curve for (+)-catechin:lysine 1:1. (E) Dose-response curve for (+)-catechin:lysine 1:2. All data are shown as means ± SEM. ∗∗∗P < 0.005
compared to a same dose of EGCG using two-way ANOVA; ##P < 0.01, ###P < 0.005 compared to vehicle treatment using one-way ANOVA with Dunnett’s
multiple comparison test.
significantly less migratory compared to cells treated with EGCG
at a dose of 100 µM (Figure 5A). Compared to vehicle, EGCG
was inefficient to prevent cancer cell migration independently of
cancer cell killing at a dose of 100 µM (Figure 5B). (+)-Catechin
did not influence the migratory activity of the cells (Figure 5C).
Comparatively, (+)-catechin:lysine 1:1 (Figure 5D) and (+)-
catechin:lysine 1:2 (Figure 5E) significantly decreased cancer
cell migration. (+)-Catechin:lysine 1:2 was the most effective,
with a reduction in cancer cell migration by ∼35 to ∼50% at
doses≥1 µM. (+)-Catechin:lysine 1:1 inhibited∼25–30% cancer
cell migration at doses of 1 and 100 µM, with no statistically
significant effects at 10 µM (P = 0.06). D/L-lysine alone did not
affect SiHa-F3 cell migration (Figure 5F).
A comparative analysis of the effects of catechins on SiHa-F3
cells is shown in Table 1.
(+)-Catechin:Lysine 1:2, But Not
Epigallocatechin-3-gallate, Inhibits
Experimental Melanoma Metastasis in
Mice
Finally, we evaluated the capability of catechins to decrease
metastatic take in mice in vivo. SiHa cells are only weakly
metastatic in SCID mice (Cairns and Hill, 2004), and SiHa-
F3 cells did not generate quantifiable lung metastases (data not
shown). We therefore used spontaneously metastatic B16F10
cancer cells that were pretreated with catechins and administered
intravenously to immunocompetent syngeneic C57BL/6JRj mice.
B16F10 cells are weakly metastatic, but the proportion of
metastatic progenitor cells, hence metastatic take in the
lungs after tail vein injection, can be increased by triggering
mitochondrial superoxide production with a nanomolar dose of
rotenone (Porporato et al., 2014).
(+)-Catechin:lysine 1:2 had shown to be the most potent
among the tested compounds to inhibit SiHa-F3 cell migration
(Figure 5). We therefore tested the effects of the complex on
rotenone-treated B16F10 cells. In agreement with the results
obtained with SiHa-F3, 10 µM of (+)-catechin:lysine 1:2 reduced
ROS production (Figure 6A) and the migration of B16F10 cancer
cells (Figure 6B) without affecting cell survival (Figure 6C).
Rotenone, used at a low dose to promote ROS production by the
ETC (Figure 6A) and cell migration (Figure 6B; Porporato et al.,
2014), had a limited yet significant cytotoxic effect after 16 h of
treatment (Figure 6C). Together, this set of data validated our
model for next in vivo assays.
For in vivo experiments, B16F10 cells were treated for
6 h with 20 nM of rotenone (to render the cells highly
metastatic) ± 10 µM of EGCG + 2 lysines (mol/mol) or (+)-
catechin:lysine 1:2 or vehicle (DMSO 0.2%) before intravenous
injection. Data revealed that (+)-catechin:lysine 1:2, but not
EGCG + 2 lysines, significantly prevented rotenone-induced
metastatic take in the lungs of mice (Figure 6D).
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FIGURE 5 | (+)-Catechin:lysine complexes and EGCG, but not (+)-catechin, inhibit SiHa-F3 cancer cell migration. (A–E) SiHa-F3 cancer cell migration was evaluated
with a Boyden chamber assay using FBS (0.15%) as chemoattractant and 16 h as an endpoint. Cells were treated with increasing doses of EGCG (N = 2, n = 6–18),
(+)-catechin (N = 2, n = 6–12), (+)-catechin in a 1:1 complex with lysine (N = 2, n = 11–12), and (+)-catechin in a 1:2 complex with lysine (N = 3, n = 17–18). The five
panels show the same sets of data with different statistical analyses to compare individual treatments to reference compound EGCG (A) or to vehicle treatment set
as 100% (B–E). (A) The graph shows the dose-response curves of the four treatments for comparison. (B) Dose-response curve for EGCG. (C) Dose-response
curve for (+)-catechin. (D) Dose-response curve for (+)-catechin:lysine 1:1. (E) Dose-response curve for (+)-catechin:lysine 1:2. (F) SiHa-F3 cancer cell migration was
evaluated with a Boyden chamber assay using FBS (0.15%) as chemoattractant and 16 h as an endpoint. Cells were treated with increasing doses of D/L-lysine
monohydrochloride (N = 2, n = 12). All data are shown as means ± SEM. ∗∗∗P < 0.005 compared to a same dose of EGCG using two-way ANOVA; #P < 0.05,
###P < 0.005 compared to vehicle treatment using one-way ANOVA with Dunnett’s multiple comparison test.
TABLE 1 | Activities of catechin derivatives on SiHa-F3 cancer cells.
EGCG (+)-Catechin (+)-Catechin:lysine 1:1 (+)-Catechin:lysine 1:2
Concentration for ROS inhibition∗ ≥1 µM ≥10 µM ≥0.1 µM ≥10 µM
Cytotoxic concentration# ≥10 µM >100 µM ≥100 µM >100 µM
Concentration for NAD(P)H oxidase inhibition$ ≥10 µM >100 µM ≥100 µM >100 µM
Antimigratory concentrationˆ ≥1 µM and <100 µM
independently of cytotoxicity
>100 µM ≥1 µM ≥1 µM
Determined with: ∗CM-H2-DCFDA, #crystal violet, $MTT, ˆtranswell assays with 0.15% FBS as chemoattractant.
DISCUSSION
This study aimed to test whether catechins have the capability
to prevent tumor metastasis. We report that, among tested
compounds, (+)-catechin:lysine 1:2 prevents tumor take of
mouse melanoma cells in mouse lungs, unveiling a particularly
attractive compound for future developments ultimately aimed
to repress metastatic cancer dissemination.
Mitochondrial superoxide promotes cancer metastasis by
increasing mitochondrial H2O2 levels and activating Src kinase,
downstream intermediates of the TGF-β pathway and focal
adhesion kinase family member Pyk2 (Porporato et al., 2014),
the latter acting as a prometastatic effector (Wendt et al., 2013).
Experimentally, increased mitochondrial superoxide production
can result from a natural selection of metastatic progenitor
cell traits or from increased electron leak when the ETC is
partially inhibited with, e.g., a low dose of rotenone. Such models,
namely SiHa-F3 and rotenone-treated B16F10 cancer cells
(Porporato et al., 2014), were used in the present study. Because
mitochondrial ROS promote tumor metastasis, mitochondrial
ROS scavenging interferes with the metastatic cascade. Indeed,
it was previously demonstrated that metastatic prevention can
be achieved in mice with mitochondria-targeted superoxide
scavenger mitoTEMPO (Dikalova et al., 2010; Nazarewicz et al.,
2013; Porporato et al., 2014). In this study, our aim was to identify
other compounds for future clinical applications.
We focused on catechins for their known antioxidant
activities, and we further reasoned that positively charged (+)-
catechin:lysine complexes could be of particular interest for
their theoretical mitochondrial tropism. Accordingly, our in vitro
data evidenced that (+)-catechin:lysine complexes have different
effects than (+)-catechin. Although all tested (+)-catechins
had similar antioxidant properties (comparable dose-response
curves), only (+)-catechin:lysine 1:1 and (+)-catechin:lysine 1:2
were capable of inhibiting cancer cell migration at concentrations
≤100 µM. (+)-Catechin did not inhibit cancer cell migration
at all, and EGCG, the most potent antioxidant that we tested,
did not impair the migration of surviving cells. Thus, the
antimigratory activities of catechins are not linked to their general
antioxidant potential. Our in vivo data further showed that
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FIGURE 6 | (+)-Catechin in a 1:2 complex with lysine, but not EGCG, inhibits the metastatic take of B16F10 melanoma cell in the lungs of mice. (A–C) B16F10
mouse melanoma cells were treated with vehicle (DMSO 0.1%) and rotenone (20 nM) alone or in combination with 10 µM of (+)-catechin in a 1:2 complex with
lysine. (A) ROS level in cancer cells was measured after a 6 h treatment (N = 2, n = 16). (B) Cancer cell migration was evaluated with a Boyden chamber assay using
FBS (0.5%) as chemoattractant and 16 h as an endpoint (N = 2, n = 8). (C) Cancer cell viability was measured by crystal violet staining following a 16 h treatment
(N = 2, n = 16). (D) Metastatic take to the lungs was determined in C57BL/6JRj mice that received a tail vein injection of 1,000,000 syngeneic B16F10 melanoma
cells. Cancer cells were pretreated for 6 h with vehicle (DMSO 0.2%; n = 6) or rotenone alone (20 nM; n = 8) or in combination with EGCG + 2 lysines mol/mol
(10 µM; n = 8) or in combination with (+)-catechin in a 1:2 complex with lysine (10 µM; n = 8). Representative pictures of the lungs are shown, and the graph
displays the number of metastasis in both lungs for each animal. Dots represent individual mice and the bars the group average. ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.005, ns: P > 0.05 using one-way ANOVA with Dunnet’s (A–C) or Bonferroni’s (D) multiple comparison test.
(+)-catechin:lysine 1:2, which possesses two positive charges
at physiological pH, is more active at inhibiting metastatic
take compared to EGCG + 2 lysines. One possibility to
explain this observation is that (+)-catechin:lysine complexes,
preferentially (+)-catechin:lysine 1:2, inhibit mitochondrial ROS
generation with some selectivity in metastatic progenitor cells.
However, mitochondria-targeted superoxide probe MitoSOX
(Roelofs et al., 2015) was not sensitive enough to measure changes
of mitochondrial ROS production under basal conditions in
our model. Another possibility is that (+)-catechin:lysine 1:2
inhibits metastatic take independently of its antioxidant activity.
However, the hypothesis of a mitochondria-selective antioxidant
action of (+)-catechin:lysine 1:2 in the prevention of metastatic
take is more likely, based on the fact that metastatic take in
our model primarily depends on increase mitochondrial ROS
production by low nanomolar doses of rotenone (Porporato
et al., 2014). It is of course evident that future studies are
needed to experimentally demonstrate that (+)-catechin:lysine
1:2 accumulates in mitochondria where it acts as an antioxidant,
with as secondary aim to verify transmembrane trafficking of
this relatively highly hydrophilic compound compared to more
lipophilic mitoTEMPO. As an alternative or in addition to
enhanced mitochondrial tropism, (+)-catechin:lysine 1:2 could
have more selectivity for prometastatic pathways compared to
other polyphenols. Reference compound EGCG can indeed
modulate a large array of signaling pathways and enzymes,
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including JAK/STAT, MAPK, PI3K/Akt, Wnt, Notch, DNA
methyl-transferases, dihydrofolate reductase, and glutamate
dehydrogenase, to name only a few (Li C. et al., 2006;
Singh et al., 2011). Pleiotropic effects of EGCG can
further explain its propensity to decrease NAD(P)H oxidase
activity (Li H. L. et al., 2006 and our MTT assays) and
to kill cancer cells (Kil et al., 2011; Yu et al., 2014).
Paradoxically, EGCG can have pro-oxidant activities: upon
oxidation, it forms auto-oxidative quinone derivatives that
generate superoxide and the hydroxyl radical (Azam et al.,
2004).
An important question raised by our study is the stable
formation of catechin:lysine complexes. Although direct
chemical evidence is currently lacking, we provide biological
evidence in favor of the existence of such complexes, at
least in the case of (+)-catechin. First, different responses
of cancer cells to (+)-catechin, (+)-catechin:lysine 1:1 and
(+)-catechin:lysine 1:2 revealed that the presence of lysine is
important. However, adding lysine was not sufficient to provide
antimetastatic properties, as illustrated by the inability of EGCG
+ 2 lysines to interfere with metastatic take in vivo, whereas
(+)-catechin:lysine 1:2 was highly effective. Lysine alone had
no effects. Second, 1-mM stock solutions of the complexes
were made before experiments, and all in vitro experiments
were conducted in commercial DMEM that contains 800 µM
of L-lysine. The fact that (+)-catechin in these conditions did
not inhibit cancer cell migration, whereas (+)-catechin:lysine
1:1 and (+)-catechin:lysine 1:2 did at doses ≥1 µM, suggests
that stable complexes were formed in stock solutions but not
in DMEM. (+)-Catechin:lysine 1:1 and (+)-catechin:lysine 1:2
are therefore likely to be relatively stable chemical entities
governed by hydrogen bounds and charge interactions, as
proposed in Figure 1. Finally, EGCG admixed with 2 lysines
had no antimetastatic effects at the concentrations that we
tested, even if EGCG was at least as antioxidant as (+)-
catechin:lysine 1:2. It is therefore possible that, in contrast
with (+)-catechin characterized by a diphenol group, EGCG
with two triphenol groups does not form stable complexes
with lysines. This could possibly be due to steric hindrance
and charge repulsion when lysines interact with a triphenol, a
hypothesis that requires chemical evaluation. Alternatively, if
EGCG:lysine complexes would be formed, they may not reach
mitochondria.
Of note, EGCG and (+)-catechin could have antimetastatic
effect in models of spontaneous metastasis, where EGCG can
interfere with pathways controlling early steps of the metastatic
process (Khan and Mukhtar, 2010; Maruyama et al., 2014;
Zhang et al., 2016) and (+)-catechin with the degradation of
collagen (Menon et al., 1999). Molecularly, (+)-catechin was
reported to increase the number of pepsin-resistant cross-links
in collagen, rendering collagen less soluble and more resistant
to collagenase than native collagen (Niebes, 1977; Pontz et al.,
1982). However, the effect of (+)-catechin on collagen does not
explain decreased metastatic take in our model, as collagen of
recipient mice was never exposed to (+)-catechin. Of further
note, our data also show that high doses of EGCG do not
inhibit cancer cell migration independently of cancer cell killing.
This could be linked to the pleiotropic actions of EGCG,
but this hypothesis, at this stage of research, is still largely
speculative. More generally, we do not believe that general
antioxidants are reliable to treat cancer because they interfere
non-selectively with many redox systems in malignant as well as
in non-malignant cells.
CONCLUSION
We report that (+)-catechin:lysine 1:2 significantly inhibits
cancer cell migration in a model of superinvasive human cervix
cancer cells in vitro and highly significantly inhibits metastatic
take in a mouse melanoma model in vivo. This property was
not shared with (+)-catechin or EGCG. Even if not definitive,
we further provide elements suggesting that (+)-catechin:lysine
1:2 is a stable complex. While further experiments are needed
to confirm the antimetastatic effects of (+)-catechin:lysine
1:2 in additional cancer models including in mice bearing
primary metastatic tumors and treated systemically (this will
require to determine the stability of the complex in vivo), we
believe that our study brings concrete elements in support of
the development of catechin:lysine complexes for metastatic
prevention in cancer.
AUTHOR CONTRIBUTIONS
VP led the experimental work. VP, PP, PD, TV, and MB
performed the experiments. VP, PP, PD, TV, MB, and PS analyzed
the data. BM, PN, and PS designed the experimental approach.
BM and PN provided test compounds. VP and PS wrote the
manuscript. PS obtained financial support and directed the study.
VP, PP, PD, TV, MB, BM, PN, and PS critically reviewed the
manuscript.
FUNDING
This work was supported by Interuniversity Attraction Poles
(IAP) grant #UP7-03 from the Belgian Science Policy Office
(BELSPO), an Action de Recherche Concertée from the
Communauté Française de Belgique (ARC 14/19-058), the Belgian
Fonds National de la Recherche Scientifique (F.R.S.-FNRS), the
Fonds Joseph Maisin, the Louvain Foundation and the Télévie.
At the time of the study, PS was a Senior Research Associate,
PP a Postdoctoral Researcher and VP a Ph.D. Fellow of the
F.R.S.-FNRS. MB is a Télévie Ph.D. Fellow.
ACKNOWLEDGMENTS
The authors thank Morgane Tardy for excellent technical
assistance and Claude Remacle-Laborie for administrative
assistance.
Frontiers in Pharmacology | www.frontiersin.org 9 December 2017 | Volume 8 | Article 869
fphar-08-00869 November 28, 2017 Time: 11:37 # 10
Payen et al. (+)-Catechin:Lysine 1:2 for the Prevention of Cancer Metastasis
REFERENCES
Assi, M., and Rebillard, A. (2016). The janus-faced role of antioxidants in cancer
cachexia: new insights on the established concepts. Oxid. Med. Cell. Longev.
2016:9579868. doi: 10.1155/2016/9579868
Azam, S., Hadi, N., Khan, N. U., and Hadi, S. M. (2004). Prooxidant property of
green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications
for anticancer properties. Toxicol. In Vitro 18, 555–561. doi: 10.1016/j.tiv.2003.
12.012
Berridge, M. V., and Tan, A. S. (1993). Characterization of the cellular
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT): subcellular localization, substrate dependence, and involvement of
mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys.
303, 474–482. doi: 10.1006/abbi.1993.1311
Bonner, M. Y., and Arbiser, J. L. (2014). The antioxidant paradox: what are
antioxidants and how should they be used in a therapeutic context for cancer.
Future Med. Chem. 6, 1413–1422. doi: 10.4155/fmc.14.86
Butler, T. P., and Gullino, P. M. (1975). Quantitation of cell shedding into efferent
blood of mammary adenocarcinoma. Cancer Res. 35, 512–516.
Cairns, R. A., and Hill, R. P. (2004). A fluorescent orthotopic model of metastatic
cervical carcinoma. Clin. Exp. Metastasis 21, 275–281. doi: 10.1023/B:CLIN.
0000037729.75981.9e
Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., and Munn,
L. L. (2000). Mosaic blood vessels in tumors: frequency of cancer cells in
contact with flowing blood. Proc. Natl. Acad. Sci. U.S.A. 97, 14608–14613.
doi: 10.1073/pnas.97.26.14608
Das, N. P., and Griffiths, L. A. (1967). Studies on flavonoid metabolism.
Biosynthesis of (+)-[14C]catechin by the plant Uncaria gambir Roxb. Biochem.
J. 105, 73–77.
Dikalova, A. E., Bikineyeva, A. T., Budzyn, K., Nazarewicz, R. R., McCann, L.,
Lewis, W., et al. (2010). Therapeutic targeting of mitochondrial superoxide in
hypertension. Circ. Res. 107, 106–116. doi: 10.1161/CIRCRESAHA.109.214601
Gupta, G. P., and Massague, J. (2006). Cancer metastasis: building a framework.
Cell 127, 679–695. doi: 10.1016/j.cell.2006.11.001
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A.,
Imanishi, H., et al. (2008). ROS-generating mitochondrial DNA mutations
can regulate tumor cell metastasis. Science 320, 661–664. doi: 10.1126/science.
1156906
Jacobs, C., Hutton, B., Ng, T., Shorr, R., and Clemons, M. (2015). Is there a role
for oral or intravenous ascorbate (vitamin C) in treating patients with cancer?
A systematic review. Oncologist 20, 210–223. doi: 10.1634/theoncologist.2014-
0381
Khan, N., and Mukhtar, H. (2010). Cancer and metastasis: prevention and
treatment by green tea. Cancer Metastasis Rev. 29, 435–445. doi: 10.1007/
s10555-010-9236-1
Kil, I. S., Jung, K. H., Nam, W. S., and Park, J. W. (2011). Attenuated mitochondrial
NADP+-dependent isocitrate dehydrogenase activity enhances EGCG-induced
apoptosis. Biochimie 93, 1808–1815. doi: 10.1016/j.biochi.2011.06.025
Klein, E. A., Thompson, I. M. Jr., Tangen, C. M., Crowley, J. J., Lucia, M. S.,
Goodman, P. J., et al. (2011). Vitamin E and the risk of prostate cancer:
the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306,
1549–1556. doi: 10.1001/jama.2011.1437
Langley, R. R., and Fidler, I. J. (2011). The seed and soil hypothesis revisited–the
role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer
128, 2527–2535. doi: 10.1002/ijc.26031
Le Gal, K., Ibrahim, M. X., Wiel, C., Sayin, V. I., Akula, M. K., Karlsson, C., et al.
(2015). Antioxidants can increase melanoma metastasis in mice. Sci. Transl.
Med. 7, 308re8. doi: 10.1126/scitranslmed.aad3740
Li, C., Allen, A., Kwagh, J., Doliba, N. M., Qin, W., Najafi, H., et al. (2006). Green tea
polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase.
J. Biol. Chem. 281, 10214–10221. doi: 10.1074/jbc.M512792200
Li, H. L., Huang, Y., Zhang, C. N., Liu, G., Wei, Y. S., Wang, A. B., et al. (2006).
Epigallocatechin-3 gallate inhibits cardiac hypertrophy through blocking
reactive oxidative species-dependent and -independent signal pathways. Free
Radic. Biol. Med. 40, 1756–1775. doi: 10.4142/jvs.2007.8.2.121
Liotta, L. A., Kleinerman, J., and Saidel, G. M. (1974). Quantitative relationships of
intravascular tumor cells, tumor vessels, and pulmonary metastases following
tumor implantation. Cancer Res. 34, 997–1004.
Maruyama, T., Murata, S., Nakayama, K., Sano, N., Ogawa, K., Nowatari, T.,
et al. (2014). (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human
colorectal cancer. Oncol. Rep. 31, 625–633. doi: 10.3892/or.2013.2925
Menon, L. G., Kuttan, R., and Kuttan, G. (1999). Anti-metastatic activity of
curcumin and catechin. Cancer Lett. 141, 159–165. doi: 10.1016/S0304-
3835(99)00098-1
Milkovic, L., Siems, W., Siems, R., and Zarkovic, N. (2014). Oxidative stress and
antioxidants in carcinogenesis and integrative therapy of cancer. Curr. Pharm.
Des. 20, 6529–6542. doi: 10.2174/1381612820666140826152822
Murphy, M. P. (2008). Targeting lipophilic cations to mitochondria. Biochim.
Biophys. Acta 1777, 1028–1031. doi: 10.1016/j.bbabio.2008.03.029
Nazarewicz, R. R., Dikalova, A., Bikineyeva, A., Ivanov, S., Kirilyuk, I. A., Grigor’ev,
I. A., et al. (2013). Does scavenging of mitochondrial superoxide attenuate
cancer prosurvival signaling pathways? Antioxid. Redox Signal. 19, 344–349.
doi: 10.1089/ars.2013.5185
Niebes, P. (1977). “Action of (+)-catechin on connective tissue,” in Flavonoids and
Bioflavonoids, eds L. Farkas, M. Gabor, and F. Kallay (Amsterdam: Elsevier),
347–361.
Niebes, P., Vineze, A., Roba, J., Lambelin, G., Matagne, D., Hanon, E., et al.
(1981). Salts of (+)-catechine, their preparation and use, and compositions
containing these salts. U.S. Patent No 4,285,964. Washington, DC: U.S. Patent
and Trademark Office.
Oliveira, M. R., Nabavi, S. F., Daglia, M., Rastrelli, L., and Nabavi, S. M. (2016).
Epigallocatechin gallate and mitochondria-a story of life and death. Pharmacol.
Res. 104, 70–85. doi: 10.1016/j.phrs.2015.12.027
Ozben, T. (2015). Antioxidant supplementation on cancer risk and during
cancer therapy: an update. Curr. Top. Med. Chem. 15, 170–178. doi: 10.2174/
1568026615666141209160918
Pontz, B. F., Krieg, T., and Muller, P. K. (1982). (+)-Cyanidanol-3 changes
functional properties of collagen. Biochem. Pharmacol. 31, 3581–3589.
doi: 10.1016/0006-2952(82)90579-2
Porporato, P. E., Payen, V. L., Baselet, B., and Sonveaux, P. (2015). Metabolic
changes associated with tumor metastasis, part 2: mitochondria, lipid and
amino acid metabolism. Cell. Mol. Life Sci. 73, 1349–1363. doi: 10.1007/s00018-
015-2100-2
Porporato, P. E., Payen, V. L., Perez-Escuredo, J., De Saedeleer, C. J., Danhier, P.,
Copetti, T., et al. (2014). A mitochondrial switch promotes tumor metastasis.
Cell Rep. 8, 754–766. doi: 10.1016/j.celrep.2014.06.043
Porporato, P. E., and Sonveaux, P. (2015). Paving the way for therapeutic
prevention of tumor metastasis with agents targeting mitochondrial superoxide.
Mol. Cell. Oncol. 2:e968043.doi: 10.4161/23723548.2014.968043
Roelofs, B. A., Ge, S. X., Studlack, P. E., and Polster, B. M. (2015). Low
micromolar concentrations of the superoxide probe MitoSOX uncouple neural
mitochondria and inhibit complex IV. Free Radic. Biol. Med. 86, 250–258.
doi: 10.1016/j.freeradbiomed.2015.05.032
Russo, G. L., Tedesco, I., Spagnuolo, C., and Russo, M. (2017). Antioxidant
polyphenols in cancer treatment: friend, foe or foil? Semin. Cancer Biol. 46,
1–13. doi: 10.1016/j.semcancer.2017.05.005
Sang, S., Lee, M. J., Hou, Z., Ho, C. T., and Yang, C. S. (2005). Stability of tea
polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers
under common experimental conditions. J. Agric. Food Chem. 53, 9478–9484.
doi: 10.1021/jf0519055
Singh, B. N., Shankar, S., and Srivastava, R. K. (2011). Green tea
catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives
and clinical applications. Biochem. Pharmacol. 82, 1807–1821. doi:
10.1016/j.bcp.2011.07.093
Tan, A. S., Baty, J. W., Dong, L. F., Bezawork-Geleta, A., Endaya, B., Goodwin, J.,
et al. (2015). Mitochondrial genome acquisition restores respiratory function
and tumorigenic potential of cancer cells without mitochondrial DNA. Cell
Metab. 21, 81–94. doi: 10.1016/j.cmet.2014.12.003
Wendt, M. K., Schiemann, B. J., Parvani, J. G., Lee, Y. H., Kang, Y., and
Schiemann, W. P. (2013). TGF-beta stimulates Pyk2 expression as part
of an epithelial-mesenchymal transition program required for metastatic
outgrowth of breast cancer. Oncogene 32, 2005–2015. doi: 10.1038/onc.
2012.230
Yu, Y., Deng, Y., Lu, B. M., Liu, Y. X., Li, J., and Bao, J. K. (2014). Green
tea catechins: a fresh flavor to anticancer therapy. Apoptosis 19, 1–18. doi:
10.1007/s10495-013-0908-5
Frontiers in Pharmacology | www.frontiersin.org 10 December 2017 | Volume 8 | Article 869
fphar-08-00869 November 28, 2017 Time: 11:37 # 11
Payen et al. (+)-Catechin:Lysine 1:2 for the Prevention of Cancer Metastasis
Zhang, J., Lei, Z., Huang, Z., Zhang, X., Zhou, Y., Luo, Z., et al. (2016).
Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth
and metastasis by targeting TRAF6 activity. Oncotarget 7, 79557–79571.
doi: 10.18632/oncotarget.12836
Conflict of Interest Statement: Manuscript data are included in patent
application WO2016/075161A1, of which some of the authors are inventors.
VALORE SA owns patent application WO2014/184197A1 on the use of
(+)-catechin:lysine complexes. Ongoing follow-up studies are financed in
part by BePharBel Manufacturing and the Région Wallonne de Belgique
(projects CATECHIN-1 and CATECHIN-2).
The other authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential conflict
of interest.
Copyright © 2017 Payen, Porporato, Danhier, Vazeille, Blackman, May, Niebes and
Sonveaux. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 11 December 2017 | Volume 8 | Article 869
